Overview

Evaluation of ADG20 for the Prevention of COVID-19

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Adagio Therapeutics, Inc.